Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165498 | 0.88 | TAS2R14 (0.60) | TAS2R14KMT2ACNR1CNR2HSD11B1 | |
| SCHEMBL22388837 | 0.80 | HDAC6 (0.54) | TAS2R14KCNA5 | |
| SCHEMBL8911635 | 0.78 | TAS2R14 (0.78) | TAS2R14KMT2ACNR1CNR2KCNA5 | |
| SCHEMBL14470114 | 0.75 | KMT2A (0.70) | TAS2R14KMT2ACNR1CNR2MEN1 | |
| SCHEMBL1279281 | 0.74 | TAS2R14 (1.00) | TAS2R14KMT2AMEN1 | |
| SCHEMBL1169654 | 0.74 | TAS2R14 (1.00) | TAS2R14KMT2AMEN1 | |
| SCHEMBL6801072 | 0.74 | RORC (0.47) | CNR1CNR2HSD11B1 | |
| SCHEMBL1951391 | 0.73 | HSD11B1 (0.56) | TAS2R14KMT2AHSD11B1MEN1 | |
| SCHEMBL28705761 | 0.72 | RECQL (0.58) | KMT2AMEN1NPSR1 | |
| SCHEMBL1169700 | 0.72 | TAS2R14 (0.75) | TAS2R14KMT2ACNR1CNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | TAS2R14 2221/4885KMT2A 1041/4885CNR1 24/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | TAS2R14 2416/4885KMT2A 906/4885CNR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.